(S)-[1-(2-aminoethyl)pyrrolidin-2-yl]methanol | 115531-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-[1-(2-aminoethyl)pyrrolidin-2-yl]methanol
• 英文别名: [(S)-1-(2-Amino-ethyl)-pyrrolidin-2-yl]-methanol；[(2S)-1-(2-aminoethyl)pyrrolidin-2-yl]methanol
• CAS: 115531-70-9
• 化学式: C₇H₁₆N₂O
• 分子量: 144.217
• InChiKey: JCCWMSYGCHUCQE-ZETCQYMHSA-N

物化性质

• 沸点：
  247.0±10.0 °C(Predicted)
• 密度：
  1.033±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-[1-(2-aminoethyl)pyrrolidin-2-yl]methanol 在 四丁基氯化铵 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.5h， 生成 tert-butyl 2-((S)-2-(chloromethyl)pyrrolidin-1-yl)ethylcarbamate
  参考文献：
  名称：

  Synthesis of DNA-Directed Pyrrolidinyl and Piperidinyl Confined Alkylating Chloroalkylaminoanthraquinones:  Potential for Development of Tumor-Selective N-Oxides

  摘要：

  A novel series of 1,4-disubstituted chloroethylaminoanthraquinones, containing alkylating chloroethylamino functionalities as part of a rigid piperidinyl or pyrrolidinyl ring-system, have been prepared. The target compounds were prepared by ipso-displacement of halides of various anthraquinone chromophores by either hydroxylated or chlorinated piperidinyl- or pyrrolidinyl-alkylamino side chains. The chloroethylaminoanthraquinones were shown to alkylate guanine residues of linearized pBR322 (1-20 mu M), and two symmetrically 1,4-disubstituted anthraquinones (compounds 14 and 15) were shown to interstrand cross-link DNA in the low nM range. Several 1,4-disubstituted chloroethylaminoanthraquinones were potently cytotoxic (IC(50) values: <= 40 nM) in human ovarian cancer A2780 cells. Two agents (compounds 18 and 19) exhibited mean GI(50) values of 96 nM and 182 nM, respectively, in the NCI human tumor cell line panel. Derivatization of the potent DNA cross-linking agent 15 to an N-oxide resulted in loss of the DNA unwinding, DNA interstrand cross-linking and cytotoxic activity of the parent molecule.

  DOI：

  10.1021/jm0608154
• 作为产物：
  描述：

  L-脯氨醇 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 5.5h， 生成 (S)-[1-(2-aminoethyl)pyrrolidin-2-yl]methanol
  参考文献：
  名称：

  Development of Nonsymmetrical 1,4-Disubstituted Anthraquinones That Are Potently Active against Cisplatin-Resistant Ovarian Cancer Cells

  摘要：

  A novel series of 1,4-disubstituted aminoanthraquinones were prepared by ipso-displacement of 1,4-difluoro-5,8-dihydroxyanthraquinones by hydroxylated piperidinyl- or pyrrolidinylalkyl-amino side chains. One aminoanthraquinone (13) was further derivatized to a chloropropylamino analogue by treatment with triphenylphosphine-carbon tetrachloride. The compounds were evaluated in the A2780 ovarian cancer cell line and its cisplatin-resistant variants (A2780/cp70 and A2780/MCP1). The novel anthraquinones were shown to possess up to 5-fold increased potency against the cisplatin-resistant cells compared to the wild-type cells. Growth curve analysis of the hydroxyethylaminoanthraquinone 8 in the osteosarcoma cell line U-2 OS showed that the cell cycle is not frozen, rather there is a late cell cycle arrest consistent with the action of a DNA-damaging topoisomerase II inhibitor. Accumulative apoptotic events, using time lapse photography, indicate that 8 is capable of fully engaging cell cycle arrest pathways in G2 in the absence of early apoptotic commitment. 8 and its chloropropyl analogue 13 retained significant activity against human A2780/cp70 xenografted tumors in mice.

  DOI：

  10.1021/jm050438f

文献信息

• [EN] MACROCYCLIC LRRK2 KINASE INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES DE KINASES LRRK2
  申请人：ONCODESIGN SA

  公开号：WO2016042089A1

  公开（公告）日：2016-03-24

  The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

  本发明涉及公式（I）的新型大环化合物及含有该化合物的组合物，作为激酶抑制剂，特别是作为LRRK2（富含亮氨酸重复激酶2）的抑制剂。此外，本发明提供了制备所述化合物的方法，以及使用它们的方法，例如作为药物或诊断试剂，特别用于治疗和/或诊断由LRRK2激酶活性特征化的疾病，如包括帕金森病和阿尔茨海默病在内的神经系统紊乱。
• Pyrrolidin-2-one derivatives having nootropic activity
  申请人：GIBIPHARMA S.p.A.

  公开号：EP0255149A1

  公开（公告）日：1988-02-03

  Pyrrolidin-2-one derivatives of formula I: wherein X = H, OH, C₂-C₇ acyloxy, C₁-C₆ alkoxy, cycloalko­xy, aralkoxy or phenoxy, n = 0 or 1 and m = 2 or 3, have a marked nootropic activity.

  式I的吡咯烷酮衍生物：其中X = H，OH，C₂-C₇酰氧基，C₁-C₆烷氧基，环烷氧基，芳基烷氧基或苯氧基，n = 0或1，m = 2或3，具有显著的智力增强活性。
• Pyrimidines as PLK inhibitors
  申请人：STADTMUELLER Heinz

  公开号：US20110086842A1

  公开（公告）日：2011-04-14

  The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物，其中A、W、X、Y、Z、Ra、Rb、Rc、R1和R3如权利要求1所定义，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。
• CANNABINOID RECEPTOR MODULATORS
  申请人：Jones Robert M.

  公开号：US20120214766A1

  公开（公告）日：2012-08-23

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及公式Ia的某些化合物及其制药组合物，其调节大麻素CB2受体的活性。本发明还涉及公式Ia的某些化合物及其制药组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎性疼痛，神经痛，由治疗副作用引起的疼痛和与骨关节炎相关的疼痛；过敏症；炎性过敏症；神经病性过敏症；急性疼痛感受；骨质疏松症；多发性硬化症相关痉挛；自身免疫疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活动和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩性侧索硬化症和帕金森病。
• Macrocyclic LRRK2 kinase inhibitors
  申请人：Oncodesign S.A.

  公开号：US10377772B2

  公开（公告）日：2019-08-13

  The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

  本发明涉及新颖的式(I)大环化合物和含有所述化合物的组合物，所述化合物可作为激酶抑制剂，特别是作为LRRK2（亮氨酸富重复激酶2）的抑制剂。此外，本发明还提供了制备所公开化合物的工艺以及使用这些化合物的方法，例如将其用作药物或诊断剂，特别是用于治疗和/或诊断以 LRRK2 激酶活性为特征的疾病，如神经系统疾病，包括帕金森病和阿尔茨海默病。